2A Pharma has a patented, highly novel and innovative vaccine platform based on adeno-associated virus-like particles (AAVLPs) that assembles into empty viral protein capsids capable of generating an antibody response against defined epitopes incorporated in the protein capsid.
2A Pharma is privately owned biotech company with the parent company in Sweden and an operating subsidiary located in Denmark. The company was founded in December 2016 in Malmö, Sweden with Søren Nielsen as CEO, John Nieland as COO and Preben Bruun-Nyzell as CFO. Shortly thereafter, the company’s first employee, Jeanette Prangsgaard, joined as Project Manager for the primary AAVLP-HPV project.
The mission is to develop novel, cost effective prophylactic and therapeutic protein vaccines based on the AAVLP platform.